Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial
Condition
On March15, 2017, Trovagene,Inc. (the Company) issued a press
release announcing its financial results for the fourth quarter
and year ended December31, 2016. A copy of the press release is
furnished as Exhibit99.1 to this Form8-K.
The information disclosed under this Item2.02, including
Exhibit99.1 hereto, is being furnished and shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended, nor shall it be incorporated by reference into
any registration statement or other document to the Securities
Act of 1933, as amended, except as expressly set forth in such
filing.
Item 8.01 Other Events
On March15, 2017, the Company issued a press release announcing
that it has signed a license agreement with Nerviano Medical
Sciences, S.r.l. that grants the Company exclusive global
development and commercialization rights to NMS-1286937, which
the Company refers to as PCM-075. PCM-075 is an oral,
investigative drug and a highly-selective adenosine triphosphate
(ATP) competitive inhibitor of the serine/threonine
polo-like-kinase 1 (PLK 1).A copy of the press release is
furnished as Exhibit99.2 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
|
99.1 |
PressReleaseofTrovagene,Inc.datedMarch15,2017. |
|
99.2 |
Press Release of Trovagene,Inc. and Nerviano Medical |
About Trovagene, Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management. Trovagene, Inc. (NASDAQ:TROV) Recent Trading Information
Trovagene, Inc. (NASDAQ:TROV) closed its last trading session up +0.10 at 1.75 with 206,374 shares trading hands.